Skip to main content
Radiopharm Theranostics Ltd logo

Radiopharm Theranostics Ltd - Investor Relations & Filings

Listed IPO Oct 2021
Ticker · RADX ISIN · US75041J1016 US Professional, scientific and technical activities
Open in API
Filings indexed 113 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country US United States of America
Listing US RADX · 3 venues

About Radiopharm Theranostics Ltd

https://radiopharmtheranostics.com/

Radiopharm Theranostics is a clinical-stage radiotherapeutics company developing a pipeline of products for both the diagnosis and treatment of cancer. The company focuses on creating first-in-class radiopharmaceuticals that address significant unmet needs in oncology. Its development strategy leverages a diverse range of proprietary platforms, including antibodies, nanobodies, peptides, and small molecules, to target novel cancer pathways. By avoiding common industry targets, the company aims to develop differentiated and precise therapies to improve patient outcomes.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-12-29 English
Regulatory Filings 2025
Regulatory Filings
2025-12-29 English
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to a registration statement on Form F-3. It details the offering and sale of ordinary shares and American Depositary Shares (ADSs) by Radiopharm Theranostics Limited, including information about a private placement, selling shareholders, and the terms of the offering. The document is a formal disclosure document used to register securities for sale to the public and does not contain financial statements or management discussion of financial results. It is not an earnings release, annual report, or any other financial report type. It is a capital markets document related to financing and share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-12-23 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of American Depositary Shares (ADSs) by Radiopharm Theranostics Limited, including the terms of the sales agreement, underwriting commission, and risk factors. The document is a registration and offering document related to capital raising activities, specifically describing the sale of securities and the terms of the offering. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing unrelated to capital raising. The presence of terms like 'prospectus supplement', 'sales agreement', 'offering price', and 'underwriting compensation' clearly indicate this is a capital/financing update document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support a high confidence level.
2025-12-23 English
REPORT OF FOREIGN PRIVATE ISSUER
Director's Dealing Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes an explanatory note about the publication of three announcements titled 'Change of Director's Interest Notice' for three individuals. The document explicitly states it is a report of changes in director's interests (share transactions by directors). There is no financial data or detailed report content, only references to director's dealings. The document length is short (2846 characters), and it includes exhibits of director's interest notices. This fits the definition of Director's Dealing (DIRS) filings, which report personal share transactions by company directors and executives. Therefore, the correct classification is DIRS with high confidence.
2025-12-19 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form F-3 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) by Radiopharm Theranostics Limited. It is a registration statement under the Securities Act of 1933, used for registering securities to be offered to the public. The text includes details about the securities being registered, the selling shareholders, the offering process, and legal disclaimers. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to the registration of securities for sale. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or notice, so it is not an RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2025-12-17 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.